A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction e 40% (L

Project: Other project

Project Details

StatusActive
Effective start/end date1/21/211/20/26

Funding

  • Bayer HealthCare Pharmaceuticals: $23,014.62